Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 15Plasma cell 9Other hematologic neoplasm 6CNS 1

Conditions

Brain Neoplasms 2313Glioblastoma 2016Glioma 1402Central Nervous System Neoplasms 692Astrocytoma 668Neuroblastoma 647Gliosarcoma 480Oligodendroglioma 405Neoplasms 405Breast Neoplasms 327Medulloblastoma 307Carcinoma, Non-Small-Cell Lung 256Meningioma 229Recurrence 224Sarcoma 215Melanoma 207Neoplasm Metastasis 202Ependymoma 200Lung Neoplasms 199Neurofibromatosis 1 169Lymphoma 162Meningeal Carcinomatosis 138Osteosarcoma 135Ovarian Neoplasms 132Wilms Tumor 123Precursor Cell Lymphoblastic Leukemia-Lymphoma 123Head and Neck Neoplasms 117Lymphoma, Non-Hodgkin 116Diffuse Intrinsic Pontine Glioma 113Rhabdomyosarcoma 107

Interventions

fludarabine 1Leukapheresis 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cytokine Release Syndrome × CNS × Clear all
NCT02761915 2021-08-17

A Phase I Trial of Anti-GD2 T-cells (1RG-CART)

Cancer Research UK

Phase 1 Completed
17 enrolled 17 charts
CNS

Cytokine Release Syndrome, Neuroblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡